Non-Small Cell Lung Cancer (NSCLC): Recent Advances in Clinical Diagnosis and Treatment
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 25 May 2026 | Viewed by 28
Special Issue Editor
Interests: non-small cell lung cancer; radiodiagnosis; radiomics; precision medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Non-small cell lung cancer (NSCLC) remains a leading cause of global cancer-related mortality, driving an urgent need for innovations in both diagnosis and therapy. The tissue biopsy remains the gold standard for initial diagnosis; liquid biopsy excels in tracking clonal evolution and emerging resistance mechanisms during treatment. The management of advanced non-small cell lung cancer (NSCLC) has been transformed by the synergy between targeted therapies and immunotherapy.
These include the approval of checkpoint inhibitors and a variety of targeted therapies, which require comprehensive biomarker testing. These advances collectively signify a shift towards more precise, dynamic, and patient-tailored NSCLC management. It is not only due to efforts in screening for detection of early-stage disease but also due to remarkable advances in the treatment of metastatic NSCLC.
Radiotherapy remains a cornerstone in the management of non-small cell lung cancer (NSCLC), with recent innovations reshaping its therapeutic role. Advanced delivery techniques such as IMRT, IGRT, and SBRT have enhanced precision, enabling higher tumor control with reduced toxicity. A major research focus is the integration of radiotherapy with systemic therapies, including chemotherapy, targeted agents, and immunotherapy. Synergistic effects have been observed, as radiotherapy can modulate the tumor microenvironment and enhance antigen presentation, thereby potentiating immune checkpoint inhibition. Clinical trials are exploring combinations with PD-1/PD-L1 and CTLA-4 inhibitors, showing promising outcomes in locally advanced and metastatic settings. Concurrent chemoradiotherapy remains the standard in unresectable stage III NSCLC, with subsequent consolidation immunotherapy further improving survival. Targeted therapies combined with radiotherapy are under investigation, particularly for tumors harboring EGFR or ALK alterations, though optimal sequencing and dosing strategies are still under definition. Adaptive radiotherapy and biomarker-driven selection may further refine patient stratification. Overall, the integration of radiotherapy with systemic agents is paving the way for more personalized, multimodal treatment paradigms in NSCLC.
This Special Issue will include articles and narrative reviews on the current treatment, as well as future perspectives for the management of NSCLC.
Prof. Dr. Cesare Guida
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel screening tool
- cancer biomarkers
- predictive marker of immunotherapy
- targeted therapy
- radiotherapy
- non-small cell lung cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
